Dear Kyle Bass,
Please contact me to discuss the work of Dr. Denise L Faustman and the TNF alpha working group.
I also have personal experience with BCG and Faustman's work is worthy of your support.
See eg
faustmanlab.org
pubmed.org faustman dl
pubmed.org ristori + BCG
I am sure the below will start to make you think about humira, enbrel, remicade etc
Cell Mol Life Sci. 2005 Aug;62(16):1850-62.
The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis.
Abstract
Excess levels of tumor necrosis factor-alpha (TNF-alpha) have been associated with certain autoimmune diseases. Under the rationale that elevated TNF-alpha levels are deleterious, several anti-TNF-alpha therapies are now available to block the action of TNF-alpha in patients with autoimmune diseases with a chronic inflammatory component to the destructive process. TNF-alpha
antagonists have provided clinical benefit to many patients, but their
use also is accompanied by new or aggravated forms of autoimmunity. Here
we propose a mechanistically based hypothesis for the adverse events
observed with TNF-alpha antagonists, and argue for the opposite therapeutic strategy: to boost or restore TNF-alpha
activity as a treatment for some forms of autoimmunity. Activation
defects in the transcription factor nuclear factor kappaB leave
autoreactive T cells sensitive to TNF-alpha-induced apoptosis. Treatment with TNF-alpha,
by destroying autoreactive T cells, appears to be a highly targeted
strategy to interrupt the pathogenesis of type 1 diabetes, lupus and
certain forms of autoimmunity.
Hayman Capital Management, L.P. is an SEC-registered asset
management firm based in Dallas, Texas. Founded by J Kyle Bass in
December 2005, Hayman Capital Management, L.P. manages assets of
privately offered pooled investment vehicles.
The
minimum investment with Hayman is $5 million.
Interested
institutional investors (including corporations, foundations,
endowments and pensions), hedge fund of funds, family offices and
high-net-worth individuals should contact:
Steele
Schottenheimer
Investor
Relations
214-347-8045
No comments:
Post a Comment